CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CytRx's potentially disease-altering approach for neurological disorders got a new lease on life after FDA accepted a revised trial protocol and said the company could continue its Phase IIb trial in amyotrophic lateral sclerosis (Lou Gehrig's disease) patients, the firm announced Dec. 2